Stefan Moese

Stefan Moese currently serves as CEO of NovaGo Therapeutics and has held the position of VP Research & Technology at Neurimmune AG since November 2018. In this role, Stefan Moese oversees scientific management for a research team focused on neurodegenerative and infectious diseases, providing mentorship and strategic guidance while implementing advanced technologies such as AAV-based delivery and gene editing. Previous positions include Director of Alternative Technologies & Automation at Novartis, where responsibilities included global management of antibody discovery approaches and strategic automation initiatives, and Group Head Screening Technology at ESBATech, enhancing screening automation for antibody development. Stefan Moese’s extensive background encompasses various roles in leading biological and technological advancements across pharmaceutical research, including significant contributions at 3-V Biosciences and the Max Planck Institute.